Vaxart 10-Q: $65.5M Cash Lasts Into Q2 2027, Before Mid-2027 COVID Data
VXRT is trading near its 52-week low of $0.32 (14% above the low).
Summary
Vaxart's Q3 10-Q shows $65.5 million in cash lasting only into Q2 2027 — before the mid-2027 Phase 2b COVID-19 data readout — with revenue down to $10.6 million and a $17.7 million net loss, and management flagging substantial doubt about going concern.
Key Events · Earnings and Guidance · VXRT
-
Going Concern Doubt Reaffirmed
Vaxart states its $65.5 million in cash, cash equivalents and short-term investments are not sufficient to fund planned operations for at least 12 months, raising substantial doubt about its ability to continue as a going concern.
-
Runway Ends Before Key Data
Management expects cash to fund operations only into Q2 2027, while full Phase 2b topline data from the 400-participant sentinel cohort and roughly 5,000 main-cohort patients is now anticipated in the first half of 2027.
-
Revenue Collapses, Loss Widens
Q3 2026 revenue fell to $10.6 million from $72.4 million a year earlier, and the net loss widened to $17.7 million, or ($0.07) per share, from $8.1 million, or ($0.04) per share.
-
BARDA Funding Cut to $344.8M
Modification No. 7 dated June 22, 2026 reduced authorized funding under the 2024 ATI-RRPV Contract to $344.8 million, with $336.4 million available for payment, after stop work orders shrank the study.
Analysis · VXRT · Life Sciences
The $65.5 million in cash funds operations only into the second quarter of 2027, while the Phase 2b COVID-19 topline data that would trigger Dynavax's $50 million election payment is now expected in the first half of 2027. Management states plainly that resources are not sufficient to fund planned operations for at least 12 months, raising substantial doubt about the ability to continue as a going concern. Revenue collapsed to $10.6 million from $72.4 million as BARDA contract work wound down, and the net loss widened to $17.7 million. Because the stock trades on OTCQX and must clear state blue-sky laws, the March 2025 ATM is effectively unusable, leaving the $24.5 million Lincoln Park equity line as the main near-term funding source — and that is priced at 97% of market, so any drawdowns dilute at these depressed levels.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VXRT was trading at $0.37 on OTC in the Life Sciences sector, with a market capitalization of approximately $88.6M. The 52-week trading range was $0.32 to $0.84. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.